Legal Opinion
In re Biogen 755 Patent Litig.
District Court, D. New Jersey
Decided September 7, 2018No. Civil Action No.: 10-2734 (CCC)(MF) (consolidated)PublishedCited by 9 opinions
1Opinion of the Court
CECCID, District Judge.
The Court held a five-week jury trial in this patent infringement action beginning on January 18, 2018. On February 23, 2018, the jury returned a verdict finding that healthcare professionals and/or patients directly infringe claims 1 and 2 of United States Patent No. 7,588,755 (the "'755 patent") when they administer or self-administer the product Rebif ® for the treatment of multiple sclerosis ("MS"), that Defendants EMD Serono, Inc. ("Serono") and Pfizer Inc. ("Pfizer") (collectively, "Defendants") have contributed to the infringement of claims 1 and 2 by selling or…
2Cases cited119 opinions
- Reeves v. Sanderson Plumbing Products, Inc.Supreme Court of the United States · 2000
- Allied Chemical Corp. v. Daiflon, Inc.Supreme Court of the United States · 1980
- Mayo Collaborative Services v. Prometheus Laboratories, Inc.Supreme Court of the United States · 2012
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Lightning Lube, Inc. v. Witco Corp.Court of Appeals for the Third Circuit · 1993
114 more not listed; retrieve them via the Exa API.
3Cited by9 opinions
- Biogen Ma Inc. v. Emd Serono, Inc.Court of Appeals for the Federal Circuit · 2020
- Apple Inc. v. Princeps Interface Technologies LLCDistrict Court, N.D. California · 2020
- BAYER HEALTHCARE PHARMACEUTICALS INC. v. BIOGEN IDEC MA INC.District Court, D. New Jersey · 2020
- California Expanded Metal Products Company v. James KleinDistrict Court, W.D. Washington · 2019
- California Expanded Metal Products Company v. James KleinDistrict Court, W.D. Washington · 2019
4 more not listed; retrieve them via the Exa API.